Cite
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
MLA
Rossari, Federico, et al. “α-FAtE: A New Predictive Score of Response to Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma.” International Journal of Cancer, vol. 154, no. 6, Mar. 2024, pp. 1043–56. EBSCOhost, https://doi.org/10.1002/ijc.34799.
APA
Rossari, F., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H. Y., Presa, J., Masi, G., Bergamo, F., Amadeo, E., Vitiello, F., Kumada, T., Sakamoto, N., Iwamoto, H., Aoki, T., Chon, H. J., … Rimini, M. (2024). α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. International Journal of Cancer, 154(6), 1043–1056. https://doi.org/10.1002/ijc.34799
Chicago
Rossari, Federico, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, et al. 2024. “α-FAtE: A New Predictive Score of Response to Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma.” International Journal of Cancer 154 (6): 1043–56. doi:10.1002/ijc.34799.